rSIV.F/HN-CFTR (Boehringer-Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial College London/University of Edinburgh/University of Oxford)

N/A

Report date: 2025/01/26 15:39:00

Base Information

Drug NamerSIV.F/HN-CFTR (Boehringer-Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial College London/University of Edinburgh/University of Oxford)
Drug Alias NameCFTR gene therapy (Sendai virus vector/F/HN-type SIV vector) (Boehringer-Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial College London/University of Edinburgh/University of Oxford)lentiviral vector-based gene therapy (Boehringer-Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial College London/University of Edinburgh/University of Oxford)
ClassificationBiologics
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator stimulants
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUk Cystic Fibrosis Gene Therapy Consortium
China Registration ClassN/A

Develop Information

Active CompaniesUk Cystic Fibrosis Gene Therapy ConsortiumUniversity Of OxfordThe University Of Edinburgh +[5] 
Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A